Covagen utilizes the unique versatility of Fynomers to create next generation biologics
Covagen is a privately held company pioneering the commercialization of Fynomers as next generation protein drugs to address unmet medical needs in inflammatory diseases and cancer. Fynomers represent a novel class of protein therapeutics. Due to their favorable biophysical properties, Fynomers with different binding specificities can be combined in a single molecule, thus creating drugs with new mechanisms of action.
Fynomers are ideally suited to enhance the potency and functionality of antibodies without compromising the antibodies' beneficial drug-like properties, and therefore, innovative products based on clinically validated antibodies can be created rapidly.